% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Bermejo:137638,
author = {J. L. Bermejo and G. Huang$^*$ and M. Manoochehri$^*$ and
K. G. Mesa$^*$ and M. Schick$^*$ and R. G. Silos and Y.-D.
Ko and T. Brüning and H. Brauch$^*$ and W.-Y. Lo and J.
Hoheisel$^*$ and U. Hamann$^*$},
title = {{L}ong intergenic noncoding {RNA} 299 methylation in
peripheral blood is a biomarker for triple-negative breast
cancer.},
journal = {Epigenomics},
volume = {11},
number = {1},
issn = {1750-192X},
address = {London},
publisher = {Future Medicine Ltd.},
reportid = {DKFZ-2018-01518},
pages = {81-93},
year = {2019},
abstract = {To identify DNA methylation biomarkers in peripheral blood
samples from triple-negative breast cancer (TNBC)
patients.We conducted an epigenome-wide association study
(EWAS): the most promising markers were identified in 233
TNBC case-control pairs (discovery set) and subsequently
validated in an independent validation set (57 TNBC patients
and 124 controls).cg06588802 (LINC00299/ID2) showed a higher
methylation in TNBC patients compared with controls
(discovery set: $3\%$ increase, p-value = 0.0009;
validation set: $2\%$ increase, p-value = 0.01).
Consistent results at four neighboring methylation probes
and the strong negative correlation (rho = -0.93) with
LINC00299 expression add plausibility to this
result.Hypermethylation of LINC00299 in peripheral blood may
constitute a useful circulating biomarker for TNBC.},
cin = {B072 / W110 / L801 / B070},
ddc = {570},
cid = {I:(DE-He78)B072-20160331 / I:(DE-He78)W110-20160331 /
I:(DE-He78)L801-20160331 / I:(DE-He78)B070-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30208740},
doi = {10.2217/epi-2018-0121},
url = {https://inrepo02.dkfz.de/record/137638},
}